These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 8692788)
1. [Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia]. Puel M; Hugonot-Diener L Presse Med; 1996 Jun; 25(22):1028-32. PubMed ID: 8692788 [TBL] [Abstract][Full Text] [Related]
2. The Global Deterioration Scale for assessment of primary degenerative dementia. Reisberg B; Ferris SH; de Leon MJ; Crook T Am J Psychiatry; 1982 Sep; 139(9):1136-9. PubMed ID: 7114305 [TBL] [Abstract][Full Text] [Related]
3. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319 [TBL] [Abstract][Full Text] [Related]
4. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment]. Papp E; Pákáski M; Drótos G; Kálmán J Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease. Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF; Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578 [TBL] [Abstract][Full Text] [Related]
6. [Adaptation and normalization of the Alzheimer's disease Assessment Scale for Spain (NORMACODEM) (II)]. Peña-Casanova J; Aguilar M; Santacruz P; Bertran-Serra I; Hernández G; Sol JM; Pujol A; Blesa R Neurologia; 1997 Feb; 12(2):69-77. PubMed ID: 9147454 [TBL] [Abstract][Full Text] [Related]
7. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects. Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580 [TBL] [Abstract][Full Text] [Related]
9. Assessing change in cognitive function in dementia: the relative utilities of the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Cognitive Drug Research system. Wesnes KA Neurodegener Dis; 2008; 5(3-4):261-3. PubMed ID: 18322407 [TBL] [Abstract][Full Text] [Related]
10. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease. Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431 [TBL] [Abstract][Full Text] [Related]
11. Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale. Talwalker S; Overall JE; Srirama MK; Gracon SI J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):39-46. PubMed ID: 8679062 [TBL] [Abstract][Full Text] [Related]
13. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale. Pyo G; Elble RJ; Ala T; Markwell SJ Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231 [TBL] [Abstract][Full Text] [Related]
14. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR). Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS; J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354 [TBL] [Abstract][Full Text] [Related]
15. [Is it pseudo-dementia? The validation of the Adas-Cog questionnaire in Hungary]. Drótos G; Pákáski M; Papp E; Kálmán J Psychiatr Hung; 2012; 27(2):82-91. PubMed ID: 22700619 [TBL] [Abstract][Full Text] [Related]
16. Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Schmeidler J; Mohs RC; Aryan M Alzheimer Dis Assoc Disord; 1998 Sep; 12(3):146-51. PubMed ID: 9772016 [TBL] [Abstract][Full Text] [Related]
17. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450 [TBL] [Abstract][Full Text] [Related]
18. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease. Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889 [TBL] [Abstract][Full Text] [Related]
19. Relationship between level of insight and severity of dementia in Alzheimer disease. CERAD Clinical Investigators. Consortium to Establish a Registry for Alzheimer's Disease. McDaniel KD; Edland SD; Heyman A Alzheimer Dis Assoc Disord; 1995; 9(2):101-4. PubMed ID: 7662321 [TBL] [Abstract][Full Text] [Related]
20. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population. Hannesdóttir K; Snaedal J Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]